# US 2012/0232862 A1 · Method and Apparatus for Computer Modeling of the Interaction Between and among Cortical and Subcortical Areas in the Human Brain for the purpose of predicting the effect of drugs in psychiatric & cognitive diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0232862 A1
- Document ID: US20120232862A1
- Status: Published application
- Kind: A1
- Application number: 13/412,626
- Filed: 2012-03-06
- Published: 2012-09-13
- Earliest claimed: 2006-11-10
- Assignees: In Silico Biosciences, Inc.
- Inventors: Hugo Geerts; Athan Spiros
- Web page: https://patentgrep.com/patent/US20120232862A1

## CPC

- G16H 50/50: for simulation or modelling of medical disorders
- G09B 23/28: for medicine
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G09B: EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS (devices for psychotechnics or for testing reaction times A61B5/16; games, sports, amusements A63; projectors, projector screens G03B)

## Abstract

A computer model of a diseased human brain includes inputs representing a drug and outputs representing the clinical effect of that drug on psychiatric and cognitive diseases. Diseases that can be modeled include psychiatric disorders, such as schizophrenia, bipolar disorder, major depression, ADHD, autism, obsessive-compulsive disorder, substance abuse and cognitive deficits therein and neurological disorders such as Alzheimer's disease, Mild Cognitive impairment, Parkinson's disease, stroke, vascular dementia, Huntington's disease, epilepsy and Down syndrome. The computer model preferably uses the biological state of interactions between and among cortico and subcortical areas of the human brain, to define the biological processes related to the biological state of the generic synapse model, the striatum, Locus Coeruleus, Dorsal raphe, hippocampus, amygdala and cortex, as well as certain mathematical relationships related to interactions among biological variables associated with the biological processes and to correlations between the biological variables and clinical effects on a clinical scale.

## Claims

### Claim 1

A method for developing a computer model of a generic receptor, comprising:
(a)(i) identifying a plurality of biological processes related to a synapse; and
(a)(ii) combining the plurality of biological processes to form a quantitative simulation of the functional concentration of a pharmacological agent in the synapse; or
(b)(i) identifying a plurality of biological processes related to a region within a brain, the plurality of biological processes including at least one biological process related to neuronal activity; and
(b)(ii) combining the plurality of biological processes to form a simulation of activity of the region.

### Claim at position 2

2-9. (canceled)

### Claim 10

A processor-readable medium comprising code representing instructions to cause a processor to:
define a plurality of biological processes related to a biological state of an animal or human striatum, Locus Coeruleus, Dorsal Raphe, Hippocampus, Amygdala and cortex, the plurality of biological processes including at least one of a first set of biological processes related to neurotransmitter dynamics and a second set of biological processes related to neuronal activation; and
define a plurality of mathematical relationships related to interactions among biological variables associated with the plurality of biological processes;
at least two biological processes from the plurality of biological processes being associated with the plurality of mathematical relationships, a combination of the plurality of biological processes and the plurality of mathematical relationships defining a simulation of the biological state of the animal or human striatum, Locus Coeruleus, Dorsal Raphe, Hippocampus, Amygdala or cortex.

### Claim at position 4

11-36. (canceled)

### Claim 37

A method for predicting clinical effects of a proposed pharmacological therapy for treating a known psychiatric disease associated with neuronal circuits within and among cortical and sub-cortical brain regions, comprising the steps:
simulating a plurality of interconnected neuronal circuits within and among different regions of a human brain afflicted with said psychiatric disease, each of the simulated circuits being separately modeled with the use of actual data about the psychiatric disease, wherein
said different regions include the cortex, and at least one of the striatum, hippocampus, amygdala, ventral tegmentum area, locus coeruleus, dorsal raphe and substantia nigra, and
the simulated circuits include
simulated interactions within and among said different brain regions through neuronal projections, and
simulated synaptic transmissions incorporating action potentials and their effect on receptors of at least one of the following types: dopaminergic, serotonergic, noradrenergic, cholinergic, glutamatergic and GABA-ergic;
simulating the functional effects of each of a plurality of known pharmacological therapies on the receptors in said simulated circuits to thereby produce corresponding simulated biological effects on the interconnected neuronal circuits;
deriving a regression equation quantitatively correlating said simulated biological effects of said known therapies with the known clinical effects of said therapies on a clinical scale related to said known psychiatric disease;
adjusting at least some parameters associated with said simulated circuits in order to develop modified simulated circuits resulting in a regression equation output having increased confidence measures of correlation between said simulated biological effects and said known clinical effects:
simulating the functional effects of a proposed pharmacological therapy on the receptors in said modified simulated circuits to thereby produce corresponding simulated biological effects on the interconnected neuronal circuits and inputting said simulated biological effects of said proposed pharmacological therapy into said regression equation; and
outputting from the regression equation a predicted quantitative clinical effect of the proposed pharmacological therapy on said clinical scale, together with a corresponding confidence measure for said predicted quantitative clinical effect,
wherein the steps are performed in a programmed computer.

### Claim 38 (depends on 37)

The method of claim 37, further comprising the step of using the simulated biological effects of said known therapies from the modified simulated circuits and the known clinical effects of said known therapies to derive a revised regression equation.

### Claim 39 (depends on 37)

The method of claim 37, wherein said psychiatric disease is selected from the group consisting essentially of schizophrenia, bipolar disorder, major depression, ADHD, autism, obsessive-compulsive disorder, substance abuse and cognitive deficits.

### Claim 40 (depends on 37)

The method of claim 37, wherein said psychiatric disease is schizophrenia.

### Claim 41 (depends on 37)

The method of claim 37, wherein the proposed pharmacological therapy is selected from a plurality of cerebro-active therapeutic agents.

### Claim 42 (depends on 37)

The method of claim 37, wherein the proposed pharmacological therapy includes a combination of different pharmacological agents each having a respective proposed dose.

### Claim 43 (depends on 37)

The method of claim 37, wherein the proposed pharmacological therapy includes a proposed dose of least one pharmacological agent having unknown clinical effects on said clinical scale.

### Claim 44 (depends on 37)

The method of claim 37, wherein the proposed pharmacological therapy includes a proposed dose of at least one known pharmacological agent.

### Claim 45 (depends on 37)

The method of claim 37, wherein at least some of the actual data used to model the simulated neuronal circuits includes known circadian profiles of physiological parameters to thereby vary at least some of the simulated biological effects over the course of a 24 hour day.

### Claim 46 (depends on 37)

The method of claim 37, wherein at least some of the actual data used to model the parameters of the simulated neuronal circuits is specific to one or more genotypes, whereby the predicted clinical effects will be applicable to those specific genotypes.

### Claim 47 (depends on 37)

The method of claim 37, wherein at least some of the actual data used to model functional effects of pharmacological therapies on the receptors in the simulated neuronal circuits reflects drug plasma levels.

### Claim 48 (depends on 47)

The method of claim 47, wherein at least some of the actual data used to model functional effects of pharmacological therapies on the receptors in the simulated neuronal circuits reflects distribution of receptor densities.

### Claim 49 (depends on 48)

The method of claim 48, further comprising the steps:
defining a sample of virtual patients each having a respective plasma and receptor density profile; and
for each virtual patient in the sample, predicting a respective quantitative clinical effect of the proposed pharmacological therapy.

### Claim 50 (depends on 37)

The method of claim 37, wherein the predicted quantitative clinical effect is measured on more than one clinical scale.

### Claim 51 (depends on 50)

The method of claim 50, wherein the predicted quantitative clinical effect includes clinical efficacy.

### Claim 52 (depends on 50)

The method of claim 50, wherein the predicted quantitative clinical effect includes side-effect liability.

### Claim 53 (depends on 50)

The method of claim 50, wherein the predicted quantitative clinical effect includes both clinical efficacy and side-effect liability.

### Claim 54 (depends on 37)

The method of claim 37, further comprising the steps:
separately predicting a respective quantitative clinical effect on the same clinical scale for each of several proposed pharmacological therapies; and
using those predicted clinical effects to rank the proposed pharmacological therapies.

### Claim 55 (depends on 37)

The method of claim 37, further comprising the steps:
varying receptor activation states in simulated neuronal synapses;
selecting receptor activation states which result in a predicted clinical effect above a predetermined threshold;
deriving a desired pharmacological target profile from the selected receptor activation states; and
outputting a predicted clinical effect for a pharmacological therapy having the desired pharmacological target profile.
